Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence

Introini, Ugo; Gimeno, Ana Torres; Scotti, Fabrizio; Setaccioli, Marco; Giatsidis, S. M.; Bandello, Francesco

doi:10.1007/s00417-012-1955-2

Cited by 35 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, previous reports have suggested that functional long-term prognosis of PED is generally poor, even under anti-VEGF treatment. 29,34 Some studies have reported an association of vascularized PED with poor functional outcomes; 31,35 while others have found an association between poor functional outcomes and baseline PED height. 30 It is interesting to note that we found a better short-term functional improvement for eyes that presented SRF at baseline.…”

Section: Discussionmentioning

confidence: 99%

Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

Dirani

Ambresin

Marchionno

et al. 2015

American Journal of Ophthalmology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

Dirani

Ambresin

Marchionno

et al. 2015

American Journal of Ophthalmology

View full text Add to dashboard Cite

“…Recent studies have shown variable outcomes associated with anti-VEGF therapy for this condition. 1,[6][7][8][9][10][11][12][13][14][15][16][17][18][19] In 2012, Introini et al 13 studied 132 eyes with vPED or retinal angiomatous proliferation lesions treated with PDT, PDT and intravitreal corticosteroid (IVT),or anti-VEGF therapy over 10 years. At 12 months after treatment, there was marked worsening of vision for eyes treated with PDT or PDT and IVT, and mild decreased vision for eyes treated with anti-VEGF injections despite favorable anatomic outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies evaluated the outcomes of ranibizumab for treating vPED due to AMD, but not comparing the results of various doses of ranibizumab. 1,[6][7][8][9][10][11][12][13][14][15][16][17][18][19] Our prospective study addressed the benefits and risks of 2.0 vs 0.5 mg ranibizumab for treating vPED due to AMD on a monthly as well as pro-re nata (PRN) basis for up to 12 months.…”

Section: Introductionmentioning

confidence: 99%

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

Chan

Abraham

Sarraf

et al. 2014

Eye

View full text Add to dashboard Cite

Summary statement Intravitreal high dose (2 mg) ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated retinal pigment epithelial detachment in eyes with exudative age-related macular degeneration, although it may possibly correlate with RPE tears in certain cases. Purpose This prospective study compared the outcomes of 0.5 vs 2.0 mg intravitreal ranibizumab injections (RI) for treating vascularized pigment epithelial detachment (vPED) due to age-related macular degeneration. Methods Patients with vPED were randomized to receive 2.0 vs 0.5 mg RI monthly for 12 months or for 4 months and then repeated on a pro-re nata basis. Optical coherence tomography, fundus photography, and fluorescein and indocyanine-green angiography were obtained at baseline and subsequent specific intervals. Outcome measures were best-corrected standardized visual acuities, central 1-mm thickness, surface area (SA), greatest linear diameter (GLD), heights (PED and CNV), and amount of subretinal fluid (SRF) and cystoid macular edema (CME). Results Both groups yielded reductions of the central 1-mm thickness, PED and CNV SA and PED height and GLD, SRF, and CME. Vision improvement and reduction in SRF and PED height occurred earlier for eyes receiving the 2.0 mg dose. Cataract progression was similar but RPE tears developed more often with the 2.0 mg dose. Conclusions There were similar visual and anatomical outcomes at the end of the study; however, the higher dose yielded more rapid reductions and more complete resolution of the PED, although there was possible increased tendency for an RPE tear with the higher dose.

show abstract

“…RPE tears either appear at the time of admission or occur after the applied treatment modalities. The incidence of RPE tears in PED patients secondary to ARMD is reported in 40% of patients treated with PDT and in 26% of patients treated with anti-VEGF (19) . In the literature, some publications reported a worsening of VA due to the occurrence of an RPE tear after the anti-VEGF injection.…”

Section: Discussionmentioning

confidence: 99%

One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration

Yüksel¹,

Türkçü²,

Şahin³

et al. 2013

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Purpose: Pigment epithelial detachment (PED) may be seen in all stages of agerelated macular degeneration (ARMD) and may lead to poor prognosis. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED. Methods: Medical records of 15 patients with PED secondary to ARMD were re viewed retrospectively. The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography and optical coherence tomography. Patients were treated with intravitreal ranibizumab or/and bevacizumab and followed up for a minimum of one year. PED height and best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection and again at the 1 st , 3 rd , 6 th and 12 th month after the injection. Results: The mean baseline BCVA was 0.71 ± 0.48 logarithm of the minimal angle of resolution (logMAR) unit and the mean baseline PED height was 361 ± 153 µ. The mean injection count per eye was 3.9 ± 2.9. There was a significant reduce in mean PED height (247 ± 177 µ) also in 2 eyes PED completely resolved at the end of the follow up period. The mean BCVA at 12 th month (0,69 ± 0,37) were not different from the baseline record. Conclusions: This retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period.

show abstract

Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence

Cited by 35 publications

References 38 publications

Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration

One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration

Contact Info

Product

Resources

About